We sought to derive a prognostic scoring system, which augmented the predictive power of the disease risk index (DRI) by incorporating biomarkers and validating their significance after SCT. These prognostic models were also predictive of relapse and NRM and remained valid at day 100, 12 months and 24 months post SCT.Ībstract = "Prognostic biomarkers are useful in allogeneic stem cell transplantation (SCT) to predict survival and relapse outcomes. In combination with DRI, these biomarkers significantly improved the Harrell's C statistic (excluding biomarkers: C=0.60, 95% CI: 0.57-0.64 with biomarkers: C=0.65, 95% CI: 0.62-0.69, P<0.001). Six hundred and two patients were identified through a retrospective analysis of allogeneic SCT recipients for haematological malignancy between 20 in a single centre. The outcomes of overall survival (OS) and relapse were assessed with non-relapse mortality (NRM) treated as a competing risk to relapse. Prognostic biomarkers are useful in allogeneic stem cell transplantation (SCT) to predict survival and relapse outcomes.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |